Abstract 751P
Background
With the introduction of molecular classification of endometrial cancer (EC), the importance of Lynch syndrome and hereditary EC has been emphasized. For a successful conduct of EC-therapy, the patient’s expectations, preferences, and needs should be considered. The aim of this survey was to evaluate the status quo and the patients' understanding of their own condition, including genetic counseling.
Methods
We developed an international online and paper survey with 80 questions for endometrial cancer patients. It included questions on demographics, medical history, tumor classification, therapy, preferences and expectations concerning treatment modalities.
Results
To date, 656 endometrial cancer patients (mean age: 65.0 [20.0; 92.0] years) completed the survey from a total of seven countries, mainly from Germany (56.1%) and Switzerland (40.5%). The majority of patients (77.4 %) were in follow-up and not receiving current cancer therapy, while 16.1 % were still receiving treatment, of which 6.4 % were due to cancer recurrence. Overall, 14.3% of the patients suffered from a recurrent disease. One third of patients (35.1%) reported that their tumor had been tested for molecular classification, and more than half (56.9%) did not know if this had occurred. Genetic counseling was only given to 21.7% of patients, 63.1% did not receive any form of it. From the patients understanding, 19.6% believe that a family history or genetic alteration could be responsible for tumorigenesis – 30.6% do not know. On the contrary, 68.1% of the patients answered that there were cases of cancer in their blood relatives – 19.1% had one or more cases of colorectal cancer in the family history, 13.9% endometrial, 10.9% gastric and 3.9% ovarian cancer. 16.4% of all patients had a second malignancy in their medical history. In general, 32.4 % of patients would like doctors to spend more time on explanations.
Conclusions
This survey underlines the great need for better access to molecular profiling and genetic counseling in women with endometrial cancer. Programs should be developed to empower patients and to educate medical staff.
Clinical trial identification
DRKS-ID: DRKS00025954.
Editorial acknowledgement
Legal entity responsible for the study
NOGGO e.V.
Funding
GSK Research & Development Limited.
Disclosure
J. Sehouli: Financial Interests, Institutional, Research Funding: AstraZeneca, Clovis Oncology, Merck, Pfizer, Tesaro, MSD Oncology, Roche, Bayer, PharmaMar; Financial Interests, Advisory Board: AstraZeneca, Clovis Oncology, PharmaMar, Merck, Pfizer, Tesaro, MSD Oncology, Lilly, Novocure, J&J, Roche, Ingress Health, Riemser, Sobi, GSK, Novartis; Financial Interests, Other, Honoraria, Travel, Accommodation, Expenses: AstraZeneca, Clovis Oncology, Olympus Medical Systems, PharmaMar, Tesaro, MSD Oncology; Financial Interests, Other, Honoraria: Eisai, J&J, Pfizer, Teva, GSK, Bayer; Financial Interests, Advisory Board, Travel, Accommodation, Expenses: Roche Pharma AG. M.L. Heubner: Financial Interests, Advisory Board: GSK, AstraZeneca, Roche; Financial Interests, Speaker, Consultant, Advisor: MSD, Intuitive, Olympus, GSK, AstraZeneca, Roche; Financial Interests, Leadership Role: SERGS (Society of European Gynaecological Surgery SERGS). All other authors have declared no conflicts of interest.
Resources from the same session
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
766P - A comparative study of sequential and interdigitated brachytherapy with chemoradiation in patients of locally advanced carcinoma cervix
Presenter: Shreya Singh
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11